EPO communicates intention to grant Nanexa’s PharmaShell® patent in Europe
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Kalender
| 2023-02-16 | Bokslutskommuniké 2022 |
| 2022-10-25 | Kvartalsrapport 2022-Q3 |
| 2022-07-21 | Kvartalsrapport 2022-Q2 |
| 2022-06-10 | Ordinarie utdelning NANEXA 0.00 SEK |
| 2022-06-09 | Årsstämma 2022 |
| 2022-04-20 | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | Bokslutskommuniké 2021 |
| 2021-11-10 | Kvartalsrapport 2021-Q3 |
| 2021-08-20 | Kvartalsrapport 2021-Q2 |
| 2021-05-06 | Kvartalsrapport 2021-Q1 |
| 2021-05-03 | Ordinarie utdelning NANEXA 0.00 SEK |
| 2021-02-18 | Bokslutskommuniké 2020 |
| 2020-11-12 | Kvartalsrapport 2020-Q3 |
| 2020-08-20 | Kvartalsrapport 2020-Q2 |
| 2020-06-03 | Ordinarie utdelning NANEXA 0.00 SEK |
| 2020-06-02 | Årsstämma 2020 |
| 2020-05-15 | Kvartalsrapport 2020-Q1 |
| 2020-02-28 | Bokslutskommuniké 2019 |
| 2019-11-12 | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | Kvartalsrapport 2019-Q2 |
| 2019-06-12 | Ordinarie utdelning NANEXA 0.00 SEK |
| 2019-06-11 | Årsstämma 2019 |
| 2019-05-15 | Kvartalsrapport 2019-Q1 |
| 2019-02-20 | Bokslutskommuniké 2018 |
| 2018-11-12 | Kvartalsrapport 2018-Q3 |
| 2018-08-22 | Kvartalsrapport 2018-Q2 |
| 2018-05-30 | Ordinarie utdelning NANEXA 0.00 SEK |
| 2018-05-29 | Årsstämma 2018 |
| 2018-05-15 | Kvartalsrapport 2018-Q1 |
| 2018-02-20 | Bokslutskommuniké 2017 |
| 2017-11-10 | Kvartalsrapport 2017-Q3 |
| 2017-10-23 | Extra Bolagsstämma 2017 |
| 2017-08-24 | Kvartalsrapport 2017-Q2 |
| 2017-06-13 | Ordinarie utdelning NANEXA 0.00 SEK |
| 2017-06-12 | Årsstämma 2017 |
| 2017-05-17 | Kvartalsrapport 2017-Q1 |
| 2017-02-15 | Bokslutskommuniké 2016 |
| 2016-11-16 | Kvartalsrapport 2016-Q3 |
| 2016-08-17 | Kvartalsrapport 2016-Q2 |
| 2016-05-27 | Ordinarie utdelning NANEXA 0.00 SEK |
| 2016-05-26 | Årsstämma 2016 |
| 2016-05-12 | Kvartalsrapport 2016-Q1 |
| 2016-04-06 | Extra Bolagsstämma 2016 |
| 2016-02-25 | Bokslutskommuniké 2015 |
| 2015-11-19 | Kvartalsrapport 2015-Q3 |
| 2015-08-20 | Kvartalsrapport 2015-Q2 |
Nanexa AB is pleased to announce that the European Patent Office (EPO) has today issued a communication advising that it intends to grant a European patent relating to Nanexa’s PharmaShell® technology.
Following completion of some internal checks and the necessary formal requirements, a patent will grant, all being well, within the next few months.
For additional information, please contact:
David Westberg – CEO, Nanexa AB (publ)
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com
Erik Penser Bank is the company’s Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se
About Nanexa AB (publ)
Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, a new and groundbreaking drug delivery system with great potential for a number of medical substance types and indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with several pharma companies, among others AstraZeneca.
Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).